Description

Bausch + Lomb Is Fixing Costs While Launching Products — A Margin Story in the Making?

Bausch + Lomb’s financial and operational performance in the fourth quarter of 2025 and for the full year underscores its strategic focus and execution across various business segments. The company recorded a notable increase in its financial metrics, achieving a record quarterly revenue of $1.405 billion and a full-year revenue of $5.101 billion, with constant currency growth rates of 7% and 6%, respectively. The adjusted EBITDA also marked historical highs with substantial growth, indicating effective cost management and strategic pricing initiatives. The company demonstrated strength across its three main segments: Vision Care, Surgical, and Pharmaceuticals. Vision Care achieved a 5% increase in Q4 driven by double-digit growth in its Contact Lens sub-segment, bolstered by the performance of its DD SiHy and Ultra lenses. Consumer products such as LUMIFY also contributed significantly. The successful introduction and expansion of innovative and premium products across markets fuel sectoral growth, even amid market challenges.